title: Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation.
abstract: Review of 463 heart transplants was undertaken to examine the relationship between level of panel-reactive antibody (PRA) and a standard donor-specific lymphocytotoxic crossmatch (LXM) on the incidence of death from hyperacute, acute, and chronic rejection. Death from chronic rejection was defined as being caused by graft atherosclerosis. Hyperacute rejection was diagnosed in 18 allografts, and only two recipients had PRA greater than 10% and another two a positive LXM. Five-year actuarial freedom from death caused by all forms of rejection correlated with PRA values as follows: PRA 0% to 10% (415 patients), 85%; PRA 11% to 25% (29 patients), 68%; PRA greater than 25% (19 patients), 57% (p less than 0.005). Additionally, there was a positive linear relationship between PRA and duration of acute rejection episodes in the first 3 months after transplantation. A positive retrospective donor-specific LXM was present in 42 of 401 patients; most of them (32 patients) were low positive (10% to 50% cell death), and none could be correlated with antibody specificity toward donor HLA antigens. Five-year actuarial freedom from death caused by rejection was 83% in those with a negative LXM, 74% in those with low-positive, and 79% in those with high-positive LXM (p = NS). Negative LXM result did not reduce the risk of death caused by rejection in any of the PRA subgroups. While PRA greater than 10% is a risk factor for rejection-related events, a negative LXM in patients with an elevated PRA does not reduce the risk of death resulting from acute or chronic rejection.
authors.affiliation: Department of Surgery, Presbyterian-University Hospital, Pittsburgh, Pa.
authors.forename: J
authors.initials: J
authors.lastname: Lavee
authors.forename: R L
authors.initials: RL
authors.lastname: Kormos
authors.forename: R J
authors.initials: RJ
authors.lastname: Duquesnoy
authors.forename: T R
authors.initials: TR
authors.lastname: Zerbe
authors.forename: J M
authors.initials: JM
authors.lastname: Armitage
authors.forename: M
authors.initials: M
authors.lastname: Vanek
authors.forename: R L
authors.initials: RL
authors.lastname: Hardesty
authors.forename: B P
authors.initials: BP
authors.lastname: Griffith
mesh_terms: D000206:Actuarial Analysis; D000328:Adult; D000918:Antibody Specificity / Q000276:immunology; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006680:HLA Antigens / Q000276:immunology; D016027:Heart Transplantation / Q000276:immunology / Q000401:mortality*; D006650:Histocompatibility Testing; D006801:Humans; D015994:Incidence; D008297:Male; D012307:Risk Factors; D013997:Time Factors
chemical_list: D006680:HLA Antigens